Shabanzadeh, A P
Tassew, N G
Szydlowska, K
Tymianski, M
Banerjee, P
Vigouroux, R J
Eubanks, J H
Huang, L
Geraerts, M
Koeberle, P D
Mueller, B K
Monnier, P P
Article History
Received: 23 July 2014
Revised: 24 February 2015
Accepted: 6 March 2015
First Online: 7 May 2015
Competing interests
: Mab AE12-1Y was developed by Abbvie and is property of this company. The company owns all the rights and commercial interests on the use of this antibody.